[Hormone replacement therapy (HRT) in peri- and postmenopause. Is it also allowed after treatment of breast carcinoma?].
Hormone Replacement Therapy (HRT) is an approved strategy of health care. Its characteristic features and benefits for women in the perimenopausal and postmenopausal state are represented. HRT is justifiable and necessary for prophylaxis and therapy of estrogen deficiency. The risk of breast cancer is not or only little increased. HRT can even take place after the therapy of breast cancer, if the consequences of the ovarian hormone deficiency can be diminished only by this method. Then the advantages preponderate over the theoretically possible risks. The mortality of women ist rather reduced by HRT.